Miguel Gil‐Gil

6.7k total citations
101 papers, 1.7k citations indexed

About

Miguel Gil‐Gil is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Genetics. According to data from OpenAlex, Miguel Gil‐Gil has authored 101 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Pulmonary and Respiratory Medicine, 53 papers in Oncology and 31 papers in Genetics. Recurrent topics in Miguel Gil‐Gil's work include Glioma Diagnosis and Treatment (30 papers), Advanced Breast Cancer Therapies (30 papers) and Cancer Treatment and Pharmacology (29 papers). Miguel Gil‐Gil is often cited by papers focused on Glioma Diagnosis and Treatment (30 papers), Advanced Breast Cancer Therapies (30 papers) and Cancer Treatment and Pharmacology (29 papers). Miguel Gil‐Gil collaborates with scholars based in Spain, United States and France. Miguel Gil‐Gil's co-authors include Jordi Bruna, S. Villà, Carlos Mesía, E. Verger, Francesc Graus, Carmen Balañá, Maria Martinez‐García, Núria Viñolas, Teresa Pujol and Ricardo Yayá and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Miguel Gil‐Gil

92 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Miguel Gil‐Gil Spain	23	814	619	600	396	322	101	1.7k
Joohee Sul United States	17	491 0.6×	565 0.9×	912 1.5×	328 0.8×	365 1.1×	26	1.7k
Stephanie E. Weiss United States	22	699 0.9×	987 1.6×	709 1.2×	241 0.6×	219 0.7×	64	1.7k
Josep Garcia Switzerland	12	442 0.5×	354 0.6×	471 0.8×	374 0.9×	473 1.5×	33	1.4k
Vincenzo Di Nunno Italy	21	524 0.6×	594 1.0×	353 0.6×	409 1.0×	448 1.4×	103	1.4k
Naren Ramakrishna United States	24	968 1.2×	920 1.5×	514 0.9×	315 0.8×	639 2.0×	56	2.2k
April F. Eichler United States	20	1.1k 1.3×	1.2k 2.0×	1.0k 1.7×	390 1.0×	689 2.1×	33	2.7k
Andreas M. Stark Germany	24	850 1.0×	919 1.5×	833 1.4×	415 1.0×	681 2.1×	47	2.4k
Matteo Simonelli Italy	27	691 0.8×	823 1.3×	818 1.4×	265 0.7×	439 1.4×	129	2.5k
Jimmy Ruiz United States	28	991 1.2×	1.1k 1.8×	545 0.9×	408 1.0×	562 1.7×	103	2.2k
Annika Malmström Sweden	21	664 0.8×	720 1.2×	1.2k 1.9×	785 2.0×	533 1.7×	66	2.3k

Countries citing papers authored by Miguel Gil‐Gil

Since Specialization

Citations

This map shows the geographic impact of Miguel Gil‐Gil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Miguel Gil‐Gil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Miguel Gil‐Gil more than expected).

Fields of papers citing papers by Miguel Gil‐Gil

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Miguel Gil‐Gil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Miguel Gil‐Gil. The network helps show where Miguel Gil‐Gil may publish in the future.

Co-authorship network of co-authors of Miguel Gil‐Gil

This figure shows the co-authorship network connecting the top 25 collaborators of Miguel Gil‐Gil. A scholar is included among the top collaborators of Miguel Gil‐Gil based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Miguel Gil‐Gil. Miguel Gil‐Gil is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Navarro‐Sabaté, Àurea, Rebeca Font, Josep Alfons Espinàs, et al.. (2025). Evaluating the Quality of Real-World Data on Adherence to Oral Endocrine Therapy in Breast Cancer Patients: How Real Is Real-World Data?. Cancers. 17(2). 200–200. 1 indexed citations

Pérez-García, José Manuel, Meritxell Bellet, Miguel Gil‐Gil, et al.. (2025). Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial. ESMO Open. 10(7). 105309–105309.

Blanch, Salvador, Miguel Gil‐Gil, Míriam Arumí, et al.. (2023). Observational study of HR+/HER2− metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS). Clinical & Translational Oncology. 25(10). 2950–2959. 4 indexed citations

Martinez‐García, Maria, Guillermo Velasco, Estela Pineda, et al.. (2022). Safety and Efficacy of Crizotinib in Combination with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Glioblastoma: Phase Ib GEINO 1402 Trial. Cancers. 14(10). 2393–2393. 16 indexed citations

Villacampa, Guillermo, Claudette Falato, Laia Paré, et al.. (2022). Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial. European Journal of Cancer. 174. 232–242. 4 indexed citations

Gil‐Gil, Miguel, Vanessa Moraes de Andrade, Hugo Pinheiro, et al.. (2022). Magnetic resonance imaging target fusion biopsy vs. transrectal ultrasound-guided biopsy - A comparative study of ISUP score upgrading risk in the ﬁnal radical prostatectomy specimen. Archivio Italiano di Urologia e Andrologia. 94(3). 278–284. 2 indexed citations

Shi, Zhen, Julia Wulfkuhle, Małgorzata Nowicka, et al.. (2021). Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer. Clinical Cancer Research. 28(5). 993–1003. 31 indexed citations

Jiménez, M. Martín, Christoph Zielinski, Manuel Ruíz‐Borrego, et al.. (2021). 229MO Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormone-receptor+/HER2- metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL study. Annals of Oncology. 32. S457–S458. 3 indexed citations

Sánchez‐Rovira, Pedro, et al.. (2020). A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women with Early Stage Breast Cancer in Treatment with Aromatase Inhibitor in the Adjuvant Setting. The Oncologist. 25(12). e1846–e1854. 18 indexed citations

10.

Hirschberg, Angelica Lindén, et al.. (2020). Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial. Menopause The Journal of The North American Menopause Society. 27(5). 526–534. 32 indexed citations

11.

Redondo, Andrés, Manuel Ramos Vázquez, Luís Manso, et al.. (2018). Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: results of the observational “LORENA” study. OncoTargets and Therapy. Volume 11. 5845–5852. 5 indexed citations

12.

Velasco, Roser, et al.. (2017). Neuropathic Pain and Nerve Growth Factor in Chemotherapy-Induced Peripheral Neuropathy: Prospective Clinical-Pathological Study. Journal of Pain and Symptom Management. 54(6). 815–825. 41 indexed citations

13.

García‐Tejedor, Amparo, Catalina Falo, Teresa Soler, et al.. (2017). Feasibility, accuracy and prognosis of sentinel lymph node biopsy before neoadjuvant therapy in breast cancer. A prospective study. International Journal of Surgery. 39. 141–147. 7 indexed citations

14.

Verma, Sunil, Miguel Gil‐Gil, Roberto Hegg, et al.. (2017). Ribociclib + letrozole vs placebo + letrozole in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC) and a high disease burden. Annals of Oncology. 28. i8–i8. 1 indexed citations

15.

Martinez‐García, Maria, Cristina Carrato, L. Ley, et al.. (2017). SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017). Clinical & Translational Oncology. 20(1). 22–28. 54 indexed citations

16.

Martín, Miguel, Moshe Inbar, Eva Carrasco, et al.. (2015). Phase III study of Palbociclib in combination with Exemestane vs. Capecitabine, in Hormonal Receptor (HR) positive/HER2 negative Metastatic Breast Cancer (MBC) patients with Resistance to non-steroidal Aromatase inhibitors (NSAI): PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006). Journal of Clinical Oncology. 1 indexed citations

17.

Sepúlveda-Sánchez, Juan Manuel, Cristóbal Belda-Iniesta, Miguel Gil‐Gil, et al.. (2015). A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma. Clinical & Translational Oncology. 17(9). 743–750. 11 indexed citations

18.

Coleman, Robert E., David Cameron, David Dodwell, et al.. (2014). Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. The Lancet Oncology. 15(9). 997–1006. 202 indexed citations

19.

Pernas, Sònia, Miguel Gil‐Gil, María Ochoa de Olza, et al.. (2012). Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel–FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice. Breast Cancer Research and Treatment. 134(3). 1161–1168. 14 indexed citations

20.

Domènech, Anna, et al.. (2007). Patients with Breast Cancer and Negative Sentinel Lymph Node Biopsy without Additional Axillary Lymph Node Dissection: A Follow-Up Study of up to 5 Years. Oncology. 72(1-2). 27–32. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact